Nav: Home

Samumed selected for 7 presentations in 5 therapeutic areas at ACR 2016

November 01, 2016

San Diego, CA--November 1, 2016 - Samumed, a leader in tissue regeneration, today announced it has been selected to feature seven presentations in five different therapeutic areas at the 2016 American College of Rheumatology (ACR) Annual Meeting from November 11-16 in Washington, D.C.

The ACR Annual Meeting is the premier educational event for physicians, health professionals and scientists who treat those with or at risk for arthritis, rheumatic and musculoskeletal diseases. Samumed's presentations will focus on the application of the company's novel, small-molecule Wnt pathway inhibitor compounds to treat the underlying pathology leading to the symptoms rather than the symptoms alone of the following diseases: Chronic Tendinopathy, Degenerative Disc Disease, Scleroderma, Osteoarthritis and Psoriasis.

"Samumed's unique understanding of the cell process and how to modulate it enables us to develop drugs that actually recover and restore the health of diseased tissues as opposed to simply providing symptom relief," said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. "We are excited to return to the ACR Annual Meeting with seven presentations that highlight the progress we've made in five disease areas with two of our small-molecule compounds, SM04755 and SM04690."

Samumed's technology platform is based on the company's ability to modulate a cell process known as the Wnt pathway--which regulates the self-renewal and differentiation of adult stem cells and has been implicated in hundreds of diseases, primarily in oncology and various degenerative conditions. The company currently has seven clinical-stage programs in development.

In addition to progress in rheumatology, Samumed has also made progress recently in other areas. Researchers recently completed a successful Phase I trial in Pulmonary Fibrosis and will be launching the next phase trial this year. The company expects to report results from an Androgenic Alopecia trial at a medical conference in spring 2017.

Samumed CEO Osman Kibar recently spoke about the full breadth of the company's research efforts in a presentation to the Royal Society of Medicine in London, which can be viewed at https://videos.rsm.ac.uk/video/regenerative-medicine-platform-initiative.

Abstracts about Samumed's seven ACR presentations are available online at the ACR Meeting Abstract webpage.

Below is the full list of the Samumed presentations at ACR and information about the diseases:

PRESENTATION INFORMATION

Title: Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Chronic Tendinopathy
Date: November 14, 2016
Abstract number: 1104

Title: Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma
Date: November 14, 2016
Abstract number: 1856

Title: Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Treatment for Degenerative Disc Disease
Date: November 15, 2016
Abstract number: 2120

Title: A Small Molecule, SM04690, Has Inhibitory Effects on the Wnt Pathway and Inflammation in Vitro, with Potential Implications for the Treatment of Osteoarthritis
Date: November 15, 2016
Abstract number: 2143

Title: Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee
Date: November 15, 2016
Abstract number: 2350

Title: Analysis of Pain and Function Components in Omeract-Oarsi Strict Responders from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee
Date: November 15, 2016
Abstract number: 2368

Title: Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Psoriasis
Date: November 15, 2016
Abstract number: 2704
-end-
DISEASE INFORMATION

ABOUT CHRONIC TENDINOPATHY


Chronic Tendinopathy is an inflammatory and degenerative condition caused by injuries or overuse.

ABOUT SCLERODERMA

Scleroderma is an autoimmune fibrotic disease, which presents skin manifestations among others.

ABOUT DEGENERATIVE DISC DISEASE

Degenerative Disc Disease (DDD), one of the main causes of low back pain, is characterized by degeneration of intervertebral disc, nucleus pulposus and cartilage matrix, resulting in decreased disc height and function.

ABOUT OSTEOARTHRITIS

Osteoarthritis (OA) involves thinning cartilage and increased subchondral bone. Amongst many cellular processes, inflammation has been associated with OA.

ABOUT PSORIASIS

Psoriasis is an autoimmune disease of the skin, characterized by inflammation and fibrosis, producing patches of red, itchy and scaly skin.

ABOUT SAMUMED, LLC

Based in San Diego, CA, Samumed is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.

Samumed, LLC

Related Osteoarthritis Articles:

Major savings possible with app-based osteoarthritis treatment
Osteoarthritis treatment conducted digitally via an app costs around 25% of what conventional care costs, according to a study from Lund University in Sweden published in the research journal PLOS ONE.
New approach to treating osteoarthritis advances
Injections of a natural 'energy' molecule prompted regrowth of almost half of the cartilage lost with aging in knees, a new study in rodents shows.
Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients.
Certain jobs linked to higher risk of knee osteoarthritis
Workers in jobs that typically involve heavy lifting, frequent climbing, prolonged kneeling, squatting, and standing face an increased risk of developing knee osteoarthritis.
App helps reduce osteoarthritis pain
By performing a few simple physical exercises daily, and receiving information about their disease regularly, 500 osteoarthritis patients were able to on average halve their pain in 6 months -- and improve their physical function.
Osteoarthritis can increase your risk for social isolation
In a study published in the Journal of the American Geriatrics Society, researchers examined information from the European Project on OSteoArthritis (EPOSA) study.
High rates of opioid prescriptions for osteoarthritis
Opioids work against severe pain but the risks of side effects and addiction are high.
Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.
3D printing may help treat osteoarthritis
In a Journal of Orthopaedic Research study, scientists used 3D printing to repair bone in the joints of mini-pigs, an advance that may help to treat osteoarthritis in humans.
Finger joint enlargements may be linked to knee osteoarthritis
Heberden's nodes (HNs) are bony enlargements of the finger joints that are readily detectable in a routine physical exam and are considered hallmarks of osteoarthritis.
More Osteoarthritis News and Osteoarthritis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.